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Abstract
Objective
We aimed to investigate neurophysiological and clinical effects of common krait envenom-
ing, including the time course and treatment response.
Methodology
Patients with definite common krait (Bungarus caeruleus) bites were recruited from a Sri
Lankan hospital. All patients had serial neurological examinations and stimulated concentric
needle single-fibre electromyography (sfEMG) of orbicularis oculi in hospital at 6wk and
6–9mth post-bite.
Principal Findings
There were 33 patients enrolled (median age 35y; 24 males). Eight did not develop neuro-
toxicity and had normal sfEMG. Eight had mild neurotoxicity with ptosis, normal sfEMG; six
received antivenom and all recovered within 20–32h. Seventeen patients developed severe
neurotoxicity with rapidly descending paralysis, from ptosis to complete ophthalmoplegia,
facial, bulbar and neck weakness. All 17 received Indian polyvalent antivenom a median
3.5h post-bite (2.8–7.2h), which cleared unbound venom from blood. Despite this, the paral-
ysis worsened requiring intubation and ventilation within 7h post-bite. sfEMG showed
markedly increased jitter and neuromuscular blocks within 12h. sfEMG abnormalities grad-
ually improved over 24h, corresponding with clinical recovery. Muscle recovery occurred in
ascending order. Myotoxicity was not evident, clinically or biochemically, in any of the
patients. Patients were extubated a median 96h post-bite (54–216h). On discharge, median
8 days (4–12days) post-bite, patients were clinically normal but had mild sfEMG
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abnormalities which persisted at 6wk post-bite. There were no clinical or neurophysiological
abnormalities at 6–9mth.
Conclusions
Common krait envenoming causes rapid onset severe neuromuscular paralysis which
takes days to recover clinically consistent with sfEMG. Subclinical neuromuscular dysfunc-
tion lasts weeks but was not permanent. Antivenom effectively cleared venom but did not
prevent worsening or reverse neuromuscular paralysis.
Author Summary
Common krait bites cause muscular paralysis due to the venom disrupting communica-
tion between the nerves and muscles. This becomes life-threatening for the patient if there
is paralysis of the muscles used for breathing. We studied the severity of paralysis, long
term effects and the value of antivenom treatment in authenticated Indian krait bite
patients from Sri Lanka. In addition to standard treatment with antivenom, the patients
had single-fibre electromyography done, a sensitive neurophysiological test that detects
the abnormalities of communication between the nerves and muscles. Half of the patients
had severe paralysis and required mechanical ventilation, and the remainder had mild or
no effects. Antivenom was given to all patients with severe paralysis and most with mild
effects. However, despite antivenom binding all free venom after it was administered, it
did not prevent or reverse already developed paralysis. Clinically evident paralysis resolved
after a few days, but the neurophysiological abnormalities lasted for weeks. No permanent
neurological damages were noted at 6 to 9 months after the snake bite.
Introduction
Globally snake envenoming is a major cause of morbidity and mortality in the rural tropics [1].
Neurotoxicity causing paralysis is one of the major clinical syndromes of snake envenoming,
and occurs mainly with elapids (Australasian elapids, American coral snakes, Asian kraits and
some cobra species)[2,3].Envenoming may result in prolonged hospital stay if ventilatory sup-
port is available or significant mortality where such medical resources are not available. Despite
the magnitude of the health impact of neurotoxic snake envenoming, it continues to be associ-
ated with several unresolved issues of clinical importance[2].
Envenoming due to krait (Genus: Bungarus) bites is a common, serious health issue in
South and South-East Asia. Common krait (Bungarus caeruleus) is distributed throughout
South Asia, and is responsible for large numbers of cases of severe neurotoxic envenoming
each year[4]. It results in a descending flaccid paralysis progressing to life threatening respira-
tory paralysis unless mechanical ventilation is available[5–7]. Krait bites typically occur at
night and are not painful, so many patients do not notice the bite and continue sleeping[7–10],
which delays medical care.
Neuromuscular paralysis in krait envenoming is characterized by progressive descending
paralysis. Krait venom contains β-bungarotoxins, which are presynaptic neurotoxins with
phospholipase A2 activity and considered to be the major cause of paralysis[11]. The pre-syn-
aptic action is irreversible and is the reason that once paralysis develops it is not reversed with
antivenom[12].
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The pathophysiology of neuromuscular paralysis in snake envenoming remains poorly
understood. This is due to the lack of detailed clinical studies of authenticated bites that report
the time course of paralysis, including the recovery of paralysis, and very few studies of neuro-
physiological function in snake envenoming[2]. There is also little evidence for the effective-
ness of antivenom in reversing neuromuscular paralysis[13,14]. Neurophysiological testing
could provide objective evidence of the progression and recovery of neurotoxicity, and the
response to antivenom. Previous neurophysiological testing in krait bites with nerve conduc-
tion studies and repetitive nerve stimulation tests, provide some information on krait neuro-
toxicity[15]. Single fibre electro-myography (sfEMG) is a more sensitive test of neuromuscular
function[16]. It has only been reported in one study of neuromuscular paralysis from Papuan
taipan envenoming.[17]Better methods to measure neuromuscular dysfunction in neurotoxic
envenoming will improve our understanding of neuromuscular paralysis and the clinical bene-
fit of antivenom.
This study aimed to describe detailed neurological examinations in patients with krait
envenoming, the use sfEMG to objectively measure the time related progression and recovery
of neuromuscular paralysis and the relationship to serum venom concentrations.
Materials and Methods
Ethics statement
Ethical approval was granted by the research ethics review committees of the University of Per-
adeniya, Sri Lanka, the Rajarata University of Sri Lanka, and Monash University, Australia.
Written informed consent was sought prior to the recruitment of all patients. For patients aged
16 and 17 years consent was also obtained from the patient’s parent or guardian.
Study setting and the patients
This study is part of a prospective study of all snakebites admitted from April to October 2014
to the Teaching Hospital, Anuradhapura, a tertiary care centre and the largest hospital in the
north central province of Sri Lanka. The region has one of the highest incidences of snakebite
in Sri Lanka.
Patients aged 16 years or over with definite common krait (B. caeruleus) bites were
recruited. Cases were authenticated as common krait bites by either expert snake identification
or detection of krait venom in patient serum. All patients presenting with live or dead speci-
mens of the offending snakes (Fig 1A), had the snake identified by one author (AS) who is a
herpetologist. Patients with clinical suspicion of a common krait bite had serum tested for krait
venom by venom-specific enzyme-immunoassay.
Data collection
All patients with suspected krait envenoming had a complete neurological examination on
admission to hospital, then repeat examinations every 2h for the first 24h post-bite, and then
every 4h for the remainder of their hospital stay. After discharge patients had a full neurological
examination at six weeks and six months post-bite to detect residual neurological impairment.
The Medical Research Council scale for muscle strength[18] was used wherever appropriate.
For the assessment of respiratory muscles, tidal volume was measured using a spirometer. Pto-
sis was graded from grade I to III using a visual analogue scale, with complete ptosis being
grade III. Weak or sluggish eye movements in one or all directions was considered to be partial
ophthalmoplegia and absent eye movements in all directions, complete ophthalmoplegia. At
each time point patients were specifically examined for features of autonomic neurotoxicity
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(heart rate, blood pressure, lacrimation, sweating and salivation), central effects (level of con-
sciousness and occulocephalic reflexes) and myotoxic effects (muscle pain and tenderness,
both local and general).
Clinical assessments were done by one author (AS) or medically qualified clinical research
assistants. All assessments performed by clinical research assistants were reviewed by AS and
approximately one third were reviewed by another medically trained author (SS). In addition
to a neurological assessment, all patients had a full clinical examination on admission, at 12h
and 24h post-bite, and then daily until discharged. Local effects included pain, swelling, paraes-
thesia or regional lymphadenopathy and non-specific systemic effects were defined as head-
ache, nausea, vomiting or abdominal pain. All assessments were recorded using a pre-
formatted clinical data form.
Antivenom administration was decided by the treating physician. All patients who received
antivenom in this study received 20 vials of Indian polyvalent antivenom as the first dose from
VINS Bioproducts (batch numbers: 01AS11119, 01AS11121, 01AS13100, 01AS14025,
01AS14026, 01AS14035). No patient in this study received a second antivenom dose. The anti-
venom infusion was ceased briefly for 5–10min in patients who developed anaphylaxis. Anti-
venom reactions were treated according to the attending physician with adrenaline,
antihistamines and corticosteroids.
Fig 1. Common krait. An adult common krait (Bungarus caeruleus) specimen, 92.5 cm in total length, that caused severe neuromuscular paralysis.
doi:10.1371/journal.pntd.0004368.g001
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During review visits patients had a routine physical and neurological examination. They
were also questioned specifically about the presence of neuromuscular effects that prevented
them performing routine daily work, and about any recovery of local effects.
Patients were classified into three groups based on the presence and severity of neurotoxic-
ity. The first group included patients who developed no clinical evidence of neurotoxicity. The
second group was patients with mild neurotoxicity defined as the presence of one of the follow-
ing clinical features; ptosis, ophthalmoplegia or facial muscle weakness, but not bulbar, respira-
tory or limb weakness. The third group was severe neurotoxicity defined as patients developing
paralysis that involved bulbar and respiratory muscles requiring mechanical ventilation.
Single-fibre electromyography (sfEMG)
Stimulated sfEMG of the orbicularis oculi muscle was performed using disposable concentric
needle electrodes (diameter: 0.3mm) and a portable Medelec Synergy N2 EMG system (Mede-
lec Synergy, UK). All tests were performed by AS at the bedside during the hospital admission
and in a separate examination room during review visits at 6 weeks and 6 months. In order to
establish the baseline values for stimulated sfEMG jitter for normal Sri Lankan subjects, 29
healthy individuals had sfEMG performed under the same conditions. The normal upper limits
of jitter for individual fibres and individual subjects were established as 30μs and 20.6μs respec-
tively[19].
Stimulation of the suprazygomatic branches of the facial nerve was by monopolar needle
electrode at a frequency of 10Hz, with the stimulus delivered as rectangular pulses of 0.1ms.
Stimulation intensity was increased until the appearance of visually discernible twitches of the
orbital part of the orbicularis oculi muscle. Stimulus strength did not exceed 2mA. All record-
ings were done after the stimulus intensity had reached supra-threshold for the fibre being
examined. Recording and analysis of the sfEMG followed Kouyoumdjian and Stålberg[20] and
the jitter of individual fibres was expressed as a mean consecutive difference (MCD). Neuro-
muscular block was where there was no transmission across the neuromuscular junction in
fibres on the sfEMG recording.
Common krait venom specific enzyme immunoassay
Blood samples from patients with suspected krait bites were collected on admission and at 1, 4,
8, 12 and 24h post-bite, and daily thereafter. All samples were immediately centrifuged, and
serum aliquoted and frozen at -80°C. Venom was quantified using a sandwich enzyme immu-
noassay as previously described[21–23]. In brief, rabbit IgG antibodies (provided by University
of Rajarata) were bound to microplates as well as conjugated to biotin for the sandwich enzyme
immunoassay, detecting with streptavidin-horseradish peroxidase. The lower limit of detection
for the assay was 0.2ng/ml.
Serum creatinine kinase assay
Creatine kinase (CK) activity was measured in the serum samples of patients obtained 24h
post-bite, or a close to this time point as possible if the 24h sample was unavailable. Creatine
kinase was measured using a commercially available assay kit using the CK-NAC Reageant
(Creatine Kinase, activated by N-acetylcysteine, Thermo Scientific, Middletown, VA, USA).
Analysis
Analysis of clinical and sfEMG data was done using Prism, version 6.05 (GraphPad Software,
Inc.). Continuous variables were reported as medians, range and interquartile range (IQR).
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Jitter values and creatine kinase concentrations of different patient groups were analysed using
one-way ANOVA followed by multiple comparison tests.
Results
During the study period 773 snakebite patients were admitted and 38 of these were suspected
common krait bites. Thirty one patients had the offending snake positively identified as a com-
mon krait and two others were positive for krait venom in their blood. The remaining five
cases were only suspected common krait bites based on circumstances of the bite, but had no
features of local or systemic envenoming, despite having fang marks. None of these patients
had a previous history of neurological disorders or therapeutic agents known to cause neuro-
transmission abnormalities. Table 1 provides the demographic features of the 33 confirmed
cases of common krait bites.
Table 1. Demographic features of 33 definite Indian Krait bite patients.
Age (median, range) 35 16–78
Sex (male) 24 73%
Occupation (Farmer) 22 67%
(manual laborer) 5 15%
(security personnel) 2 6%
(student) 2 6%
(Other) 2 6%
Bite time (night: 1900–0600 hrs) 30 91%
Activity (Sleeping on the ﬂoor) 22 67%
(Sleeping on the bed) 3 9%
(household work) 4 12%
(Other) 4 12%
Place (home) 25 76%
(hut in the farmland) 4 12%
(Home garden) 2 6%
(other) 2 6%
Site of bite (lower limbs) 12 36%
(upper limbs) 12 36%
(Trunk) 4 12%
(head) 1 3%
(site uncertain) 4 12%
Under inﬂuence of alcohol when snake bite took place 4 12%
Distance from the place of bite to the nearest hospital (median, range; in km) 6 1.5–20
Mode of transport used to reach the nearest hospital (motorbike) 17 52%
(Three wheeler) 10 30%
(other) 6 18%
Time since bite to reach nearest hospital (median, range; in hours) 0.87 0.16–4.5
Time since bite to reach the study hospital (median, range; in hours) 3.3 1.5–7.0
First aid and home remedies (washed the bite site) 3 9%
(local application of lime juice) 3 9%
(application of tourniquet proximal to the bite site) 3 9%
(herbal decoctions) 3 9%
Previous history of snakebites 3 9%
Total length of the offending snake (median, range; in cm) 90.6 32.2–122.2
Sex of the offending snake (female) 15 58%
doi:10.1371/journal.pntd.0004368.t001
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Clinical effects during hospital stay
Eight patients who brought the offending snake and had evidence of a bite with fang marks,
did not develop neurotoxic features during their hospital stay. None of these received anti-
venom (Table 2).
Eight patients had mild neurotoxicity and six of these received antivenom (Table 2). All
these patients had partial ptosis on admission. In one patient, this progressed to complete pto-
sis with partial ophthalmoplegia and mild facial weakness within 12h of the bite, but 2h after
antivenom was given. Two patients not receiving antivenom did not have any progression of
neurotoxicity. All eight patients were fully recovered the next day and were discharged 20 to
32h post-admission.
Seventeen patients developed severe neurotoxicity with a range of neurotoxic clinical fea-
tures on admission (Table 2). Three patients appeared to have altered consciousness and had
no respiratory effort on admission with oxygen saturations< 50%. These three were immedi-
ately intubated and ventilated. All 17 patients were given antivenom a median of 3.5h post-bite
Table 2. Comparison of the clinical effects and treatment of the patients who developed no neurotoxicity, mild neurotoxicity and severe neurotox-
icity following common krait envenoming.
No neurotoxicity Mild neurotoxicity Severe neurotoxicity
Number of patients 8 8 17
Hours from bite to hospitalization: median (range) 3.0 (1.5–6.0) 3.0 (1.0–6.0) 3.3 (1.5–7.0)
Days of hospital stay: median (range) 2 (1–3) 3 (2–3) 8 (4–12)
Neurotoxicity
Maximum ptosis observed
• Partial - 7 (87.5%) 5 (29.4%)
• Complete - 1 (12.5%) 12 (70.6%)
Maximum ophthalmoplegia observed
• Partial - 1 (12.5%) 3 (17.6%)
• Complete - 0 14 (82.4%)
Strabismus - - 11 (64.7%)
Facial weakness - 1 (12.5%) 17 (100%)
Neck ﬂexion weakness (power <5) - - 15 (88.2%)
Difﬁculty in swallowing - - 17 (100%)
Low pitched voice - - 12 (70.6%)
Tidal volume <250ml - - 17 (100%)
Reduced upper limb power (Power <5) - - 12 (70.6%)
Reduced lower limb power (power <5) - - 5 (29.4%)
Diminished or absent deep tendon reﬂexes 9 (52.9%)
Intubation and mechanical ventilation - - 17 (100%)
Autonomic features - - 6 (35.3%)
Other features of envenoming
Generalized myalgia 3 (32.7%) 2 (25%) 7 (41.2%)
Generalized muscle tenderness 2 (25%) 2 (25%) 7 (41.2%)
Local envenoming 5 (62.5%) 6 (75%) 9 (52.9%)
Non-speciﬁc systemic envenoming - 5 (62.5%) 13 (76.5%)
Treatment
Antivenom given - 6 (75%) 17 (100%)
Hours from bite to antivenom: median(range) - 7.5 (2.8–13.0) 3.5 (2.8–7.2)
Adverse reactions to antivenom - 6 (100%) 13 (76.5%)
doi:10.1371/journal.pntd.0004368.t002
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(2.8–7.2h). Antivenom therapy did not stop progression of neurotoxic features in any patient
and intubation and mechanical ventilation was required within 7h of the snake bite in all 17
patients. The clinical features of neurotoxicity progressed in a descending order from eyes to
peripheral limbs (Fig 2A). Five patients developed complete limb paralysis with areflexia occur-
ring within 8h of the bite (Figs 1C and 2A).
Neuromuscular function began to recover in all 17 patients on average 30h post-bite (22–
51h). Muscle groups recovered in the reverse order to that in which paralysis developed. Fig 2B
shows the time scale of the recovery of neurotoxic features. Patients were extubated a median
of 96h post-bite (54–216 h).
One patient with severe paralysis and no motor function appeared to be in a deep coma
with absent brainstem reflexes 12h post-bite. There was no recordable response on sfEMG
done 10h and 16h post-bite. The patient had slight movement of the toes in response to a ster-
nal rub 26h post-bite, but no occulocephalic reflex. The occulocephalic reflex recovered 6h
later, followed by gradual ascending recovery of all motor function and sfEMG jitter.
All 33 patients were discharged with no clinically detectable neuromuscular paralysis. How-
ever, on discharge 23 patients had no pain, touch or temperature sensation in an area of 3–8cm
diameter around the bite site. Of 23 patients who received antivenom, 19 developed an adverse
reaction and six of these developed severe anaphylaxis with hypotension (systolic blood pres-
sure<90mmHg) and tissue hypoxia (SpO2<92%) that required resuscitation. Of these, three
were intubated for the antivenom reaction before they developed respiratory muscle paralysis
due to envenoming.
Clinical effects: Long term
At 6 weeks, six of eight patients with no acute neurotoxicity, seven of eight with mild neurotox-
icity and 14 of 17 with severe neurotoxicity were reviewed. None had clinically detectable neu-
romuscular paralysis. Sixteen patients (five mild and 11 severe neurotoxicity) still had absent
pain, touch and temperature sensation around the bite site (4–7cm diameter area).
At 6 to 9 months after the krait bite, six with no acute neurotoxicity, five with mild neuro-
toxicity and ten with severe neurotoxicity were reviewed and there was no evidence of clinical
neuromuscular dysfunction. All sensory abnormalities around the bite site had resolved and
the patients stated the feeling of numbness around the bite site disappeared 2 to 3 months
post-bite.
sfEMG
sfEMG were undertaken in seven non-envenomed patients, seven with mild neurotoxicity and
ten with severe neurotoxicity. On admission, all patients with no neurotoxicity or mild neuro-
toxicity (n = 14) had a median MCD in jitter on sfEMG similar to normal controls (Figs 3A
and 4A). Two patients with mild neurotoxicity had neuromuscular blockade in 3% and 12% of
fibres respectively. The other patients had no neuromuscular block. Jitter was not markedly
increased and no blocks were seen in the no neurotoxicity and mild neurotoxicity groups
6–12h post-bite (n = 5, n = 5; Fig 4B). The median MCD was also not different from normal on
discharge, at 6 weeks and at 6 to 9 months in all patients in these two groups.
All patients with severe neurotoxicity had a high median MCD in jitter compared to nor-
mal, with most having neuromuscular blockade on admission (Figs 3B and 4A). At 6–12h
post-bite, jitter was markedly increased and there was increased neuromuscular block in
recorded fibres (Figs 4B, 5A and 5B). In two patients who had severe neurotoxicity, sfEMG
recordings showed no response during this period (9 and 10.5h post-bite respectively), indicat-
ing complete neuromuscular blockade. Eleven patients received atracurium for rapid sequence
Neuromuscular Effects of Common Krait Envenoming
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intubation. The post-intubation sfEMG for these patients was done a median of 5.8h (4.5–
23.2h) after receiving the atracurium dose.
In all patients with severe neurotoxicity, sfEMG24–36h post-bite showed improved jitter
(decreased median MCD) and decreased blocks compared to 6–12h post-bite (Fig 5A and 5B).
On discharge, the median MCD in jitter on the sfEMG was still abnormally high in 11 patients.
Of these, three had 3 to 10% fibres with blocks (10–12 days post-bite). At 6 weeks, seven of the
Fig 2. Time related change of neuromuscular paralysis. A, Noodle plot showing the evolution of paralysis in 14 patients with severe neurotoxicity. Note
the pre-antivenom events are in red; B, Scatter plots of the time taken for the complete resolution of five major clinical effects of neurotoxicity (muscle
groups), including ptosis, diplopia, external ophthalmoplegia, facial weakness, upper limb weakness and lower limb weakness in the 17 patients with severe
neuromuscular paralysis.
doi:10.1371/journal.pntd.0004368.g002
Fig 3. Superimposed and non-superimposed sfEMG recordings of the orbicularis oculi muscle of
patients following krait bites. A, recordings of a patient on admission with no neurotoxicity indicating the
normal jitter (14.5μs) and no blocks;B, high jitter (61.6μs) with intermittent blocks seen in a patient on
admission with severe neuromuscular paralysis. (The distance between two dots represents 200μV vertically
and 3ms horizontally.)
doi:10.1371/journal.pntd.0004368.g003
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fourteen patients reviewed still had high MCD jitter values (>22.6μs) and six of them had
blocks in 3 to 13% of the recorded fibres. At 6 to 9 months, ten of these patients were reviewed
and all had normal jitter with no blocks recorded.
Measurement of venom concentrations
Krait venom was not detectable in the eight non-envenomed patients. Of the six patients with
mild neurotoxicity who received antivenom, pre-antivenom blood samples of four patients
were available but no venom was detected in any. The two patients with mild neurotoxicity
who did not receive antivenom had no detectable venom in blood. Nine of the 17 patients with
severe neurotoxicity had pre-antivenom blood samples available, and krait venom was detected
in eight (0.3 to 52.2ng/ml) (Fig 6). None of the post-antivenom samples had detectable free
venom, indicating rapid and persistent binding of venom by antivenom (Fig 6).
Serum creatine kinase concentrations
Serum samples were available in 32 of the 33 study participants and had a median creatine
kinase concentration of 43 U/L (8 to 274 U/L). There were no significant differences in the cre-
atine kinase concentrations between the mild, moderate and severely envenomed groups.
Discussion
In this cohort of patients with definite common krait envenoming, about half developed life-
threatening neuromuscular paralysis that did not appear to be prevented by or respond to anti-
venom treatment. Patients who had sfEMG performed had increased jitter and increased neu-
romuscular block that correlated with the clinical severity. The neurophysiological
abnormalities improved in line with clinical recovery but were still abnormal 6 weeks after the
bite, despite the patients being clinically normal. The prolonged high jitter during the recovery
phase may represent immaturity of the motor nerve terminals undergoing the re-innervation
process. Excepting the three patients who were intubated due to antivenom reactions, all other
patients were intubated due to bulbar weakness and/or respiratory paralysis, which developed
within 7h of the bite. This demonstrates that severe neuromuscular paralysis develops rapidly.
Based on this finding it appears that patients who do not develop bulbar weakness or respira-
tory paralysis within 12h of the bite, are highly unlikely to develop severe paralysis. These fig-
ures are largely in agreement with previous reports from Sri Lanka[7,10].
Although krait venoms contain both pre-synaptic neurotoxins (β-bungarotoxins) and post-
synaptic neurotoxins (α-bungarotoxins), it is generally accepted that the pre-synaptic neuro-
toxins are more important in human envenoming[24,25]. Presynaptic neurotoxins cause irre-
versible injury. For example, the major pre-synaptic neurotoxin from the Chinese many
banded krait (Bunragus multicinctus), β-bungarotoxin, causes depletion of synaptic vesicles fol-
lowed by destruction of the motor nerve terminals in the isolated mouse phrenic nerve-hemi-
diaphragm preparation and the soleus muscle of the mouse hind limbs[12]. Common krait
venom contains β1–β5-caerulotoxins, a group of toxins similar to β-bungarotoxin, that are
most likely responsible for the paralysis in common krait bites.[26]
Ultrastructural damage and functional injury caused by β-bungarotoxin to the motor nerve
terminals recovers over about 7 days[24]. In our study, clinically detectable neurotoxicity
Fig 4. sfEMG jitter comparison across no, mild and severe neurotoxicity groups. Scatter plots of the median MCD in jitter of the three groups of patients
with common krait bites on admission (A) and 6–12 hours after the bite (B) compared to the median MCD in jitter values of normal subjects. Median and
interquartile range is shown for each group in the graph. On both occasions, the severe neurotoxicity group has significantly high median jitter compared to
the normal subjects (P<0.0001; one-way ANOVA followed by multiple comparison test).
doi:10.1371/journal.pntd.0004368.g004
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resolved 4 to 12 days post-bite, but subclinical neuromuscular dysfunction remained for at
least 6 weeks in some patients. This may be due to some motor nerve terminals taking longer
to fully recover and re-innervate muscle, and the already re-innervated muscle fibres compen-
sating for recovering fibres. sfEMG directly measures transmission across the neuromuscular
junction by measuring security of transmission to individual muscle fibres, so is more sensitive
than other neurophysiological investigations and likely to detect abnormal neurotransmission
in recovering fibres. Therefore, sfEMGmeasurements are likely to give a more accurate mea-
sure of the recovery time of neuromuscular dysfunction in snake envenoming.
One previous study reported abnormalities in nerve conduction one year after the snake
bite, particularly in patients presumed to be bitten by elapids[27]. However, this study by Bell
et al. only reported nerve conduction studies one year post-bite, with no comparison at the
time of the bite. In addition, these nerve conduction studies are not as sensitive as sfEMG, mak-
ing it difficult to interpret their results. sfEMG recordings in our study demonstrate the com-
plete recovery of neuromuscular function at 6 months, even in the patients who had severe
neuromuscular dysfunction within 24h post-bite, suggesting the findings of Bell et al. one year
post-bite are unlikely to be related to the snake bite.
In all 17 patients with severe neuromuscular paralysis, the peak or most severe effects, both
clinical and neurophysiological, were observed during the first 24h after the bite. Patients then
began to recover during day two, with considerable improvement in both neuromuscular jitter
and neuromuscular block compared to day one. In contrast, animal experiments show that the
initiation of re-innervation with motor nerve terminal sprouting occurs three to five days after
Fig 5. Time related change of sfEMG jitter and blocks in patients developed severe neurotoxicity. A, Scatter plots showing the time related change of
the median MCD in jitter of the 17 patients with severe neurotoxicity, compared to normal subjects. Note the high median of the MCD in jitter values seen
even at 6 weeks after the snakebite, compared to the normal subjects;B, scatter plots showing time related changes in the percentage of recorded fibres with
neuromuscular blocks in these patients at the same times. Neuromuscular blocks are still present 6 weeks after the snakebite.
doi:10.1371/journal.pntd.0004368.g005
Fig 6. Serum venom concentrations of 9 patients with pre-antivenom blood samples, in relation to the
time of initiation of the antivenom therapy. Pre-antivenom venom concentrations are indicated by filled
black circles and post-antivenom concentrations by filled red circles.
doi:10.1371/journal.pntd.0004368.g006
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venom inoculation [12,25]. The reason for the more rapid and marked improvement on the
second day in humans is unclear. One possible reason is that those muscle fibres of the orbicu-
laris oculi which are already denervated due to toxin induced injury by the second day, fail to
produce any response with electrical stimulation. This means they are no longer part of the
sampled fibres in the sfEMG recording. Motor nerve terminals that were less damaged are then
the ones that make up the majority of the sampled fibres falsely improving the measurement.
Although we are unable to exclude this on sfEMG, there was also clinical recovery in patients
during the second day, based on the re-appearance of deep tendon reflexes and the plantar
reflex. Further investigation is required to understand the pathophysiological basis of these
observations in human recovery.
Serum venom concentrations depend on multiple factors including the venom dose deliv-
ered, the rate of venom absorption and therefore the time post-bite, individual patient factors
that affect the pharmacokinetics of the venom (e.g. effect of patient size/weight, renal function)
and the sensitivity of the assay. Kraits inject very small amounts of venom during their bite,
explaining the low venom concentrations in our study and previous studies.[9,28] The eight
patients who had no detectable venom in blood and had no features of envenoming, were ‘dry
bites’, as previously seen among patients with common krait bites[7,9]. The absence of detect-
able venom in patients with mild neurotoxicity is more difficult to explain. The most likely
explanation is that the assay is not sensitive enough to detect the small amount of such a potent
elapid venom that can cause minor toxicity. A similar phenomena is seen with Australian
brown snake (Pseudonaja spp) venom where< 0.2ng/mL can result in a mild coagulopathy
[29]. An additional explanation is that this is due to late sampling times after the peak venom
concentrations, when venom has distributed out of the central compartment. Either way these
patients are likely to have had small venom doses from the bite. This is also the likely explana-
tion for the two patients with mild neurotoxicity who did not receive antivenom and did not
worsen. In the severe neurotoxicity group, there was also large variations in the venom concen-
trations (Fig 6).
Presynaptic neurotoxins cause irreversible nerve injury, so neurotoxicity is expected not to
respond to antivenom once it has developed[24]. Despite most patients receiving early anti-
venom and antivenom rapidly clearing free venom in blood, the paralysis worsened and
required mechanical ventilation in all 17 patients for several days. In the mildly neurotoxic
patients one patient progressed despite antivenom and two patients who did not receive anti-
venom had similar outcomes to those receiving antivenom. Antivenom cannot reverse neuro-
muscular injury and recovery occurs through the natural nerve terminal repair[24,25]. These
results demonstrate that Indian polyvalent antivenom is efficacious (binds venom) but is not
effective for common krait envenoming in Sri Lanka, because of the irreversibility of the pre-
synaptic neurotoxicity.
Antivenom was able to clear circulating free venom, so given early enough antivenom may
still be beneficial in preventing progression of neuromuscular dysfunction. This has been dem-
onstrated in studies of Papuan taipan bites where early antivenom (<6h post-bite) reduced the
number of patients requiring intubation[17]. Unfortunately, the majority of patients (19/23)
who received antivenom in our study developed acute adverse reactions, including some with
life threatening anaphylaxis. Therefore, the safety and benefits of antivenom need to be care-
fully weighed up along with the clinical status of the patient, before deciding on antivenom
therapy.
The majority of patients in this study reached a primary care centre early, but because of
concerns about antivenom reactions, antivenom was not usually administered prior to transfer
to the study hospital. If Indian polyvalent antivenom had a lower reaction rate, this would
encourage primary care doctors to administer antivenom as early as possible, and before
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transferring them to tertiary care hospital. Such an approach would help prevent neurotoxicity
in the majority of cases, without risk of life-threatening adverse reactions.
Although generalized myalgia and muscle tenderness were observed in some patients, the
normal serum creatine kinase concentrations in patients is consistent with common krait
envenoming not causing myotoxicity. Mildly elevated serum myoglobin levels were previously
reported in one envenomed krait patient in Sri Lanka,[28] but serum myoglobin is not a very
specific marker of muscle injury. Myotoxicity has been reported in envenoming by other krait
species, including B. niger [30], B.multicinctus [31] and B. candidus [32]. However, in the
study of B. candidus there were only mild elevations of creatine kinase, and the study of B.mul-
ticinctus only reports myalgia.
Coma has been previously reported in common krait envenoming [7,33]. In one study, two
patients with deep coma were reported to have electroencephalogram abnormalities, abnormal
brain stem visual and auditory evoked potentials, leading to the conclusion that krait venom
can cause cortical and brain stem effects [33]. However peptide and protein toxins are unlikely
to cross the blood brain barrier making this theoretically unlikely. In the present study, one
patient with severe paralysis had deep coma, absent brainstem reflexes and no sfEMG record-
ings. Interestingly, there was a period of time when the patient had absent brain stem reflexes
but some motor function, suggesting that the patient was more likely to have had severe paraly-
sis mimicking coma, rather than coma itself. Similar observations have previously been made
in snakebite patients in India [34–37]. The altered consciousness observed in three patients on
admission was most likely due to hypoxia secondary to respiratory muscle paralysis, rather
than any direct central effect of the venom.
sfEMG jitter results can be influenced by pre-existing medical conditions that affect the
peripheral nervous system, such as myasthenia gravis, diabetes mellitus and leprosy. None of
the patients in this study had a history of any of these conditions. Two-thirds of the patients
were farmers who may have had pre-existing neurotransmission abnormalities secondary to
chronic exposure to organophosphates. However, we did not see a difference in the jitter values
of the present cohort of patients at 6 months compared to the normal subjects, so this is
unlikely.
A limitation of the study was that sfEMG was only performed on the orbicularis oculi mus-
cle. This was done because it is one of the muscles affected earliest in snake bite paralysis and it
is convenient to access. The neuromuscular jitter and blocking correlated well with the clinical
picture indicating that this muscle is likely to be representative of the neurophysiology of the
neuromuscular paralysis in snake envenomed humans. Another limitation of the study was
that the recovery of certain muscles, e.g. neck extensors, buccinator, bulbar muscles, could not
be assessed while patients were intubated. In addition, while the patients were sedated, assess-
ment of the power of voluntary contractions of muscles was not possible. Hence the exact
sequence of muscle involvement, particularly during the recovery, could not be documented in
some patients. Finally, it is important to consider the risk of sfEMG in patients with
coagulopathy.
Our study highlights the usefulness of sfEMG as a biomarker, particularly as a research tool
on snakebite neurotoxicity. The sfEMG and clinical findings suggest that recovery occurs more
rapidly than expected, based on animal studies, and further work is required to explain this.
The study confirmed that antivenom did not reverse neurotoxicity and that if antivenom is
going to prevent neurotoxicity, it must be given much earlier, prior to development of any neu-
rotoxic effects. A placebo controlled trial is required to determine if antivenom hastens the
recovery in established neurotoxicity.
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